AR077901A1 - Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer - Google Patents

Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Info

Publication number
AR077901A1
AR077901A1 ARP100103069A ARP100103069A AR077901A1 AR 077901 A1 AR077901 A1 AR 077901A1 AR P100103069 A ARP100103069 A AR P100103069A AR P100103069 A ARP100103069 A AR P100103069A AR 077901 A1 AR077901 A1 AR 077901A1
Authority
AR
Argentina
Prior art keywords
diagnosis
antibody
cmet
prognosis
oncogenic
Prior art date
Application number
ARP100103069A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR077901A1 publication Critical patent/AR077901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se relaciona con el campo del pronostico y/o diagnosis de una enfermedad proliferativa en un paciente. Más específicamente, se relaciona con un anticuerpo con capacidad para unirse específicamente al receptor cMet humano, (receptor del HGF factor de crecimiento de hepatocitos), como así también las secuencias de aminoácidos y ácidos nucleicos que codifican este anticuerpo. Comprende asimismo el uso de dicho anticuerpo y los correspondientes procesos para la deteccion y diagnostico de trastornos patologicos oncogénicos hiperproliferativos asociados a la expresion de cMet. En ciertas realizaciones, los trastornos son trastornos oncogénicos asociados a la expresion incrementada del polipéptido cMet con respecto a lo normal o cualquier otra patología asociada a la sobreexpresion de cMet. Comprende, por ultimo, productos y/o composiciones o kits que comprenden por lo menos dicho anticuerpo para el pronostico o diagnostico de ciertos cánceres.
ARP100103069A 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer AR077901A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25

Publications (1)

Publication Number Publication Date
AR077901A1 true AR077901A1 (es) 2011-09-28

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103069A AR077901A1 (es) 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Country Status (19)

Country Link
US (2) US8673302B2 (es)
EP (2) EP2287197A1 (es)
JP (1) JP5951486B2 (es)
KR (1) KR20120051734A (es)
CN (1) CN102639564B (es)
AR (1) AR077901A1 (es)
AU (1) AU2010284944B2 (es)
BR (1) BR112012003759A2 (es)
CA (1) CA2769427C (es)
ES (1) ES2692522T3 (es)
IL (1) IL218202A (es)
IN (1) IN2012DN01322A (es)
MX (1) MX2012002139A (es)
NZ (2) NZ700437A (es)
RU (1) RU2582265C2 (es)
SG (1) SG178339A1 (es)
TW (1) TW201111781A (es)
WO (1) WO2011020925A1 (es)
ZA (1) ZA201202076B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
AR087918A1 (es) 2011-09-19 2014-04-23 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
JP2014533700A (ja) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
SG10201506881PA (en) * 2011-11-21 2015-10-29 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US9260531B2 (en) 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP6892826B2 (ja) * 2015-03-18 2021-06-23 シージェン インコーポレイテッド Ｃｄ４８抗体及びその複合体
EP3411067B1 (en) 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
PT3458102T (pt) 2016-05-17 2020-08-17 Abbvie Inc Conjugados de fármacos com anticorpo anti-cmet e métodos para o seu uso
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CN114599978A (zh) * 2019-06-06 2022-06-07 浙江冠科美博生物科技有限公司 使用c-met抑制剂治疗癌症患者的方法
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN115297889A (zh) 2020-09-01 2022-11-04 荣昌生物制药(烟台)股份有限公司 抗c-Met抗体药物偶联物及其应用
IL300952A (en) * 2020-09-08 2023-04-01 Ideaya Biosciences Inc Drug combination and tumor treatment
WO2024030341A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20050118165A1 (en) * 2001-12-27 2005-06-02 Van Andel Institute; And The Usa As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7964365B2 (en) * 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
DK1981981T3 (da) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
EP2287197A1 (en) 2011-02-23
ES2692522T3 (es) 2018-12-04
AU2010284944B2 (en) 2016-01-28
ZA201202076B (en) 2012-11-28
CA2769427A1 (en) 2011-02-24
TW201111781A (en) 2011-04-01
CN102639564B (zh) 2015-01-07
EP2467402B1 (en) 2018-08-01
CA2769427C (en) 2020-03-10
IL218202A0 (en) 2012-04-30
EP2467402A1 (en) 2012-06-27
RU2012109004A (ru) 2013-09-27
BR112012003759A2 (pt) 2017-07-11
CN102639564A (zh) 2012-08-15
NZ598194A (en) 2015-05-29
JP2013502213A (ja) 2013-01-24
RU2582265C2 (ru) 2016-04-20
AU2010284944A1 (en) 2012-03-08
IN2012DN01322A (es) 2015-06-05
WO2011020925A1 (en) 2011-02-24
US20120149031A1 (en) 2012-06-14
JP5951486B2 (ja) 2016-07-13
KR20120051734A (ko) 2012-05-22
MX2012002139A (es) 2012-03-07
US8673302B2 (en) 2014-03-18
IL218202A (en) 2017-07-31
SG178339A1 (en) 2012-03-29
NZ700437A (en) 2016-04-29
US20140295452A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
AR081696A1 (es) Anticuerpo para el diagnostico y/o pronostico de cancer
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
DOP2013000145A (es) Inmunoglobulinas de dominio variable dual biespecíficas de il-1 alfa y beta y su uso.
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
BR112016005802A2 (pt) conjugados de clorotoxina e métodos de seu uso
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
EA201291044A1 (ru) Слитый белок robo1-fc и его применение в лечении опухолей
AR095556A1 (es) Anticuerpos contra hgf y composiciones que contienen a los mismos
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
WO2012112911A3 (en) Devices and methods for optical pathology
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido

Legal Events

Date Code Title Description
FA Abandonment or withdrawal